Skip to content
Find a Provider
Peter Van Veldhuizen, M.D.

Peter Van Veldhuizen, M.D.

Cancer

UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Not Accepting New Patients

Contact

Call Center (585) 276-3000

Locations

Wilmot Cancer Institute

875 Hard Road
Webster, NY 14580

(585) 602-3150 Get Directions

About Me

Dr. Van Veldhuizen completed his residency training followed by a Hematology/ Oncology fellowship at the University of Kansas Medical Center. He is board-certified in Internal Medicine, Hematology, and Oncology. After spending much of his career in Kansas City where his primary clinical focus was th...
Dr. Van Veldhuizen completed his residency training followed by a Hematology/ Oncology fellowship at the University of Kansas Medical Center. He is board-certified in Internal Medicine, Hematology, and Oncology. After spending much of his career in Kansas City where his primary clinical focus was the treatment of Genitourinary Malignancies (GU), in 2020 he joined the University of Rochester and the Wilmot Cancer Center to lead their GU Medical Oncology Program.

Dr. Van Veldhuizen sees patients with kidney, bladder, testicular, and prostate cancer. He is involved in helping formulate multidisciplinary treatment plans, administering chemotherapy, and managing symptoms related to both the cancer and its treatment. He also has a clinical focus on cancer survivorship and addressing all aspects related to the cancer diagnosis.

Professional Background

Dr. Van Veldhuizen is a Professor of Internal Medicine at the University of Rochester Medical Center and currently leads the GU Medical Oncology Program. He also serves as the chair of the Genitourinary Working Group which provides oversight and direction for the GU Clinical Trial Research Program. ...
Dr. Van Veldhuizen is a Professor of Internal Medicine at the University of Rochester Medical Center and currently leads the GU Medical Oncology Program. He also serves as the chair of the Genitourinary Working Group which provides oversight and direction for the GU Clinical Trial Research Program. He also currently serves on the American Society of Clinical Oncology's (ASCO) Clinical Guidelines Committee which provides treatment guidelines for practicing Oncologists. He has served as a grant reviewer for the Department of Defense Prostate Cancer Research Program and is currently a committee member for an ASCO expert panel focusing on developing treatment guidelines for advanced kidney cancer.
Before coming to Rochester, he served as chair of the Kansas City Veteran Affairs Hematology/Oncology Program and then served as the Division Director of Hematology/ Oncology at the University of Kansas Medical Center. He is an advocate for addressing all aspects of the cancer diagnosis.

Certified Specialties

Internal Medicine - American Board of Internal Medicine

Faculty Appointments

Professor - Department of Medicine, Hematology/Oncology (SMD)

Credentials

Residency & Fellowship

Fellowship, Medical Oncology, University of Kansas Medical Center-Kansas City. 1989 - 1992

Residency, Internal Medicine, University of Kansas Internal Medicine Residency. 1987 - 1989

Internship, Internal Medicine, University of Kansas Internal Medicine Residency. 1986 - 1987

Education

MD | University of South Dakota School of Medicine. 1986

Research

Dr. Van Veldhuizen's research has focused on the development of novel clinical trials for the treatment of genitourinary malignancies. He has been a member of the National Clinical Trial Group, SWOG, and their Genitourinary Cancer (GU) Committee since 1992. He currently serves on their GU Executive ...
Dr. Van Veldhuizen's research has focused on the development of novel clinical trials for the treatment of genitourinary malignancies. He has been a member of the National Clinical Trial Group, SWOG, and their Genitourinary Cancer (GU) Committee since 1992. He currently serves on their GU Executive Committee and is the Chairman of SWOG's GU Cancer Survivorship Subcommittee. He also serves as the GU liaison to the Cancer Control Committees helping mentor investigators in the development of Cancer Control and Survivorship projects. He has been the national Principal Investigator (PI) or primary coordinator on SWOG trials and well as the PI on local investigator-initiated studies. He has had a focused interest in collaborating with laboratory-based scientists, helping translate those findings into the clinic. His current laboratory-based research interest is evaluating the mechanism of the spread of prostate cancer to the bone.

Clinical Trials

Efficacy of Curcumin and Piperine in Patients on Active Surveillance for Either Monoclonal Gammopathy of Unknown Significance (MGUS), Low-risk Smoldering Multiple Myeloma (SMM) or Early Stage Prostate Cancer: A Pilot Study

Lead Researcher: Peter Van Veldhuizen

To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering myeloma.

Publications

Journal Articles

Management of Metastatic Renal Clear Cell Cancer: ASCO Guideline Rapid Recommendation Update.

Singer EA, Rumble RB, Rathmell WK, Van Veldhuizen PJ,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2023 October 9 :JCO2301977. Epub 10/09/2023.

DNA Methyltransferase 1 Targeting Using Guadecitabine Inhibits Prostate Cancer Growth by an Apoptosis-Independent Pathway.

Karan D, Singh M, Dubey S, Van Veldhuizen PJ, Saunthararajah Y

Cancers.. 2023 May 1515 (10)Epub 05/15/2023.

Prostate Cancer Active Surveillance: Quality Matters.

Van Veldhuizen PJ

Journal of the National Comprehensive Cancer Network : JNCCN.. 2023 May 21 (5):529-530. Epub 1900 01 01.

Prostate Cancer Stem Cells: The Role of CD133.

Yang J, Aljitawi O, Van Veldhuizen P

Cancers.. 2022 November 514 (21)Epub 11/05/2022.

Access to urologists for participation in research: An analysis of NCI's Community Oncology Research Program landscape survey.

Ellis SD, Vaidya R, Unger JM, Stratton K, Gills J, Van Veldhuizen P, Mederos E, Dressler EV, Hudson MF, Kamen C, Neuman HB, Kazak AE, Carlos RC, Weaver KE

Contemporary clinical trials communications.. 2022 October 29 :100981. Epub 08/14/2022.

Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.

Rathmell WK, Rumble RB, Van Veldhuizen PJ, Al-Ahmadie H, Emamekhoo H, Hauke RJ, Louie AV, Milowsky MI, Molina AM, Rose TL, Siva S, Zaorsky NG, Zhang T, Qamar R, Kungel TM, Lewis B, Singer EA

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2022 June 21 :JCO2200868. Epub 06/21/2022.

Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-stage Prostate Cancer: The Men's Eating and Living Study (Cancer and Leukemia Group 70807 [Alliance]).

Kellogg Parsons J, Zahrieh D, Patel D, Mohler JL, Chen RC, Paskett ED, Liu H, Peil ES, Rock CL, Hahn O, Taylor J, Van Veldhuizen PJ, Small EJ, Morris MJ, Naughton MJ, Pierce JP, Marshall J

European urology focus.. 2022 April 30 Epub 04/30/2022.

Role of Pelvic Radiation in Management of Non-Metastatic Pathological Node-Positive Prostate Cancer: A Single Institution Experience.

Kruger J, Bylund KC, Cummings MA, Frye T, Fung C, Ghazi A, Joseph J, Messing E, Rashid H, Sahasrabdhe D, Van Veldhuizen P, Victor A, Wu G, Zhang H

International journal of radiation oncology, biology, physics.. 2021 November 1111 (3S):e298-e299. Epub 1900 01 01.

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.

Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK,

The New England journal of medicine.. 2021 April 8384 (14):1289-1300. Epub 02/13/2021.

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, ?o?nierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ,

The New England journal of medicine.. 2021 March 4384 (9):829-841. Epub 1900 01 01.

Surviving Testicular Cancer: The Role of the Contralateral Testicle.

D'souza A, Van Veldhuizen P, Fung C

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2021 February 139 (4):265-268. Epub 1900 01 01.

Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.

McFarlane JJ, Kochenderfer MD, Olsen MR, Bauer TM, Molina A, Hauke RJ, Reeves JA, Babu S, Van Veldhuizen P, Somer B, Gunuganti V, Schnadig I, George S, Page RD, Arrowsmith E, Jain RK, Zhang J, McHenry MB, Johansen JL, Vogelzang NJ

Clinical genitourinary cancer.. 2020 December 18 (6):469-476.e4. Epub 06/14/2020.

Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.

Vogelzang NJ, Olsen MR, McFarlane JJ, Arrowsmith E, Bauer TM, Jain RK, Somer B, Lam ET, Kochenderfer MD, Molina A, Doshi G, Lingerfelt B, Hauke RJ, Gunuganti V, Schnadig I, Van Veldhuizen P, Fleming M, Galamaga R, Gupta M, Hool H, Hutson T, Zhang J, McHenry MB, Johansen JL, Tykodi SS

Clinical genitourinary cancer.. 2020 December 18 (6):461-468.e3. Epub 05/16/2020.

Circulatory MIC-1 as a Determinant of Prostate Cancer Racial Disparity.

Karan D, Wick J, Dubey S, Tawfik O, Van Veldhuizen P

Cancers.. 2020 October 1812 (10)Epub 10/18/2020.

Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial.

Parsons JK, Zahrieh D, Mohler JL, Paskett E, Hansel DE, Kibel AS, Liu H, Seisler DK, Natarajan L, White M, Hahn O, Taylor J, Hartman SJ, Stroup SP, Van Veldhuizen P, Hall L, Small EJ, Morris MJ, Pierce JP, Marshall J

JAMA.. 2020 January 14323 (2):140-148. Epub 1900 01 01.

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ,

The New England journal of medicine.. 2018 April 12378 (15):1408-1418. Epub 02/08/2018.

The Role of Compounds Derived from Natural Supplement as Anticancer Agents in Renal Cell Carcinoma: A Review.

Haque I, Subramanian A, Huang CH, Godwin AK, Van Veldhuizen PJ, Banerjee S, Banerjee SK

International journal of molecular sciences.. 2017 December 3119 (1)Epub 12/31/2017.

Correlation between markers of bone metabolism and vitamin D levels in patients with monoclonal gammopathy of undetermined significance (MGUS).

Lipe B, Kambhampati S, Veldhuizen PV, Yacoub A, Aljitawi O, Mikhael J

Blood cancer journal.. 2017 December 147 (12):646. Epub 12/14/2017.

Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.

Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Quinn DI

Clinical genitourinary cancer.. 2017 December 15 (6):635-641. Epub 05/10/2017.

The Role of High Dose Interleukin-2 in the Era of Targeted Therapy.

Gills J, Parker WP, Pate S, Niu S, Van Veldhuizen P, Mirza M, Holzbeierlein JM, Lee EK

The Journal of urology.. 2017 September 198 (3):538-545. Epub 03/10/2017.

Vitamin D Impacts the Expression of Runx2 Target Genes and Modulates Inflammation, Oxidative Stress and Membrane Vesicle Biogenesis Gene Networks in 143B Osteosarcoma Cells.

Garimella R, Tadikonda P, Tawfik O, Gunewardena S, Rowe P, Van Veldhuizen P

International journal of molecular sciences.. 2017 March 1618 (3)Epub 03/16/2017.

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM.

Clark JI, Wong MKK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S

Clinical genitourinary cancer.. 2017 February 15 (1):31-41.e4. Epub 10/29/2016.

Metastatic prostate cancer in the modern era of PSA screening.

Fontenot PA, Nehra A, Parker W, Wyre H, Mirza M, Duchene DA, Holzbeierlein J, Thrasher JB, Van Veldhuizen P, Lee EK

International braz j urol : official journal of the Brazilian Society of Urology.. 2017 43 (3):416-421. Epub 1900 01 01.

Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421).

Unger JM, Griffin K, Donaldson GW, Baranowski KM, Good MJ, Reburiano E, Hussain M, Monk PJ, Van Veldhuizen PJ, Carducci MA, Higano CS, Lara PN, Tangen CM, Quinn DI, Wade JL, Vogelzang NJ, Thompson IM, Moinpour CM

Journal of patient-reported outcomes.. 2017 2 :27. Epub 06/13/2018.

Emblica officinalis extract downregulates pro-angiogenic molecules via upregulation of cellular and exosomal miR-375 in human ovarian cancer cells.

De A, Powers B, De A, Zhou J, Sharma S, Van Veldhuizen P, Bansal A, Sharma R, Sharma M

Oncotarget.. 2016 May 247 (21):31484-500. Epub 1900 01 01.

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ,

The New England journal of medicine.. 2015 November 5373 (19):1814-23. Epub 09/25/2015.

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.

Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R,

The Lancet. Oncology.. 2015 March 16 (3):338-48. Epub 02/18/2015.

Metastatic papillary renal cell carcinoma regression after cytoreductive nephrectomy.

Williams T, Rodriguez R, Murray K, Kovaleski A, Madan R, Van Veldhuizen P

Urology.. 2015 February 85 (2):283-7. Epub 1900 01 01.

Impact Study: MK-0646 (Dalotuzumab), Insulin Growth Factor 1 Receptor Antibody Combined with Pemetrexed and Cisplatin in Stage IV Metastatic Non-squamous Lung Cancer.

Huang CH, Williamson SK, Neupane P, Taylor SA, Allen A, Smart NJ, Uypeckcuat AM, Spencer S, Wick J, Smith H, Van Veldhuizen PJ, Kelly K

Frontiers in oncology.. 2015 5 :301. Epub 01/13/2016.

A potential regulatory loop between Lin28B:miR?212 in androgen-independent prostate cancer.

Borrego-Diaz E, Powers BC, Azizov V, Lovell S, Reyes R, Chapman B, Tawfik O, McGregor D, Diaz FJ, Wang X, Veldhuizen PV

International journal of oncology.. 2014 December 45 (6):2421-9. Epub 09/09/2014.

Prostate-specific antigen and prostate-specific antigen velocity as threshold indicators in 11C-acetate PET/CTAC scanning for prostate cancer recurrence.

Dusing RW, Peng W, Lai SM, Grado GL, Holzbeierlein JM, Thrasher JB, Hill J, Van Veldhuizen PJ

Clinical nuclear medicine.. 2014 September 39 (9):777-83. Epub 1900 01 01.

An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors.

Maison-Blanche P, Dakhil S, Baron A, Rottey S, Millard F, Daugaard G, Machiels JP, Conkright W, Sharma S, Soetekouw PM, Yachnin J, Sengeløv L, Van Veldhuizen P, Agarwala SS, Sémiond D, Chadjaa M, Shen L, Wade JL

Cancer chemotherapy and pharmacology.. 2014 June 73 (6):1241-52. Epub 04/10/2014.

Leukemoid reaction and autocrine growth of bladder cancer induced by paraneoplastic production of granulocyte colony-stimulating factor--a potential neoplastic marker: a case report and review of the literature.

Kumar AK, Satyan MT, Holzbeierlein J, Mirza M, Van Veldhuizen P

Journal of medical case reports.. 2014 May 138 :147. Epub 05/13/2014.

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Datar RH, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Thompson IM, Cote RJ, Vogelzang NJ

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2014 April 1032 (11):1136-42. Epub 03/10/2014.

A novel three-dimensional stromal-based model for in vitro chemotherapy sensitivity testing of leukemia cells.

Aljitawi OS, Li D, Xiao Y, Zhang D, Ramachandran K, Stehno-Bittel L, Van Veldhuizen P, Lin TL, Kambhampati S, Garimella R

Leukemia & lymphoma.. 2014 February 55 (2):378-91. Epub 05/15/2013.

Retinoic acid signaling pathways in development and diseases.

Das BC, Thapa P, Karki R, Das S, Mahapatra S, Liu TC, Torregroza I, Wallace DP, Kambhampati S, Van Veldhuizen P, Verma A, Ray SK, Evans T

Bioorganic & medicinal chemistry.. 2014 January 1522 (2):673-83. Epub 11/22/2013.

Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study.

Bhatia S, Curti B, Ernstoff MS, Gordon M, Heath EI, Miller WH, Puzanov I, Quinn DI, Flaig TW, VanVeldhuizen P, Byrnes-Blake K, Freeman JA, Bittner R, Hunder N, Souza S, Thompson JA

Journal for immunotherapy of cancer.. 2014 2 :2. Epub 01/27/2014.

A multicenter pilot study examining the role of circulating tumor cells as a blood-based tumor marker in patients with extensive small-cell lung cancer.

Huang CH, Wick JA, Sittampalam GS, Nirmalanandhan VS, Ganti AK, Neupane PC, Williamson SK, Godwin AK, Schmitt S, Smart NJ, Spencer S, Van Veldhuizen PJ

Frontiers in oncology.. 2014 4 :271. Epub 10/14/2014.

Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy.

Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI,

European journal of cancer : official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR).. 2013 November 49 (17):3648-57. Epub 08/22/2013.

Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.

Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, Tombal B, Damiao R, Marx G, Miller K, Van Veldhuizen P, Morote J, Ye Z, Dansey R, Goessl C

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2013 October 2031 (30):3800-6. Epub 09/16/2013.

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.

Quinn DI, Tangen CM, Hussain M, Lara PN, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM

The Lancet. Oncology.. 2013 August 14 (9):893-900. Epub 07/17/2013.

The perioperative management of an inferior vena caval tumor thrombus in patients with renal cell carcinoma.

Woodruff DY, Van Veldhuizen P, Muehlebach G, Johnson P, Williamson T, Holzbeierlein JM

Urologic oncology.. 2013 July 31 (5):517-21. Epub 04/21/2011.

NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200.

Fu J, Rodova M, Nanta R, Meeker D, Van Veldhuizen PJ, Srivastava RK, Shankar S

Neuro-oncology.. 2013 June 15 (6):691-706. Epub 03/12/2013.

NVP-LDE-225 (Erismodegib) inhibits epithelial-mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2R? null mice by regulating Bmi-1 and microRNA-128.

Nanta R, Kumar D, Meeker D, Rodova M, Van Veldhuizen PJ, Shankar S, Srivastava RK

Oncogenesis.. 2013 April 82 :e42. Epub 04/08/2013.

Boron chemicals in diagnosis and therapeutics.

Das BC, Thapa P, Karki R, Schinke C, Das S, Kambhampati S, Banerjee SK, Van Veldhuizen P, Verma A, Weiss LM, Evans T

Future medicinal chemistry.. 2013 April 5 (6):653-76. Epub 1900 01 01.

A second-generation 2-Methoxyestradiol prodrug is effective against Barrett's adenocarcinoma in a mouse xenograft model.

Kambhampati S, Rajewski RA, Tanol M, Haque I, Das A, Banerjee S, Jha S, Burns D, Borrego-Diaz E, Van Veldhuizen PJ, Banerjee SK

Molecular cancer therapeutics.. 2013 March 12 (3):255-63. Epub 01/03/2013.

Short-term soy isoflavone intervention in patients with localized prostate cancer: a randomized, double-blind, placebo-controlled trial.

Hamilton-Reeves JM, Banerjee S, Banerjee SK, Holzbeierlein JM, Thrasher JB, Kambhampati S, Keighley J, Van Veldhuizen P

PloS one.. 2013 8 (7):e68331. Epub 07/12/2013.

The matricellular protein CCN1/Cyr61 is a critical regulator of Sonic Hedgehog in pancreatic carcinogenesis.

Haque I, De A, Majumder M, Mehta S, McGregor D, Banerjee SK, Van Veldhuizen P, Banerjee S

The Journal of biological chemistry.. 2012 November 9287 (46):38569-79. Epub 10/01/2012.

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS,

The Lancet. Oncology.. 2012 October 13 (10):983-92. Epub 09/18/2012.

Inhibition of RalA signaling pathway in treatment of non-small cell lung cancer.

Male H, Patel V, Jacob MA, Borrego-Diaz E, Wang K, Young DA, Wise AL, Huang C, Van Veldhuizen P, O'Brien-Ladner A, Williamson SK, Taylor SA, Tawfik O, Esfandyari T, Farassati F

Lung cancer : journal of the International Association for the Study of Lung Cancer.. 2012 August 77 (2):252-9. Epub 04/10/2012.

Combination immunotherapy with prostate GVAX and ipilimumab: safety and toxicity.

Karan D, Van Veldhuizen P

Immunotherapy.. 2012 June 4 (6):577-80. Epub 1900 01 01.

Cancer immunotherapy: a paradigm shift for prostate cancer treatment.

Karan D, Holzbeierlein JM, Van Veldhuizen P, Thrasher JB

Nature reviews. Urology.. 2012 May 299 (7):376-85. Epub 05/29/2012.

A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients.

Womble PR, VanVeldhuizen PJ, Nisbet AA, Reed GA, Thrasher JB, Holzbeierlein JM

The Journal of urology.. 2011 September 186 (3):882-7. Epub 07/24/2011.

Prostate imaging modalities that can be used for complementary and alternative medicine clinical studies.

Dusing RW, Drisko JA, Grado GG, Levine M, Holzbeierlein JM, Van Veldhuizen P

The Urologic clinics of North America.. 2011 August 38 (3):343-57. Epub 1900 01 01.

Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.

Karan D, Dubey S, Van Veldhuizen P, Holzbeierlein JM, Tawfik O, Thrasher JB

Immunotherapy.. 2011 June 3 (6):735-46. Epub 1900 01 01.

Abiraterone and increased survival in metastatic prostate cancer.

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI,

The New England journal of medicine.. 2011 May 26364 (21):1995-2005. Epub 1900 01 01.

Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032.

Smith DC, Tangen CM, Van Veldhuizen PJ, Harrer GW, Golshayan A, Mills GM, Vogelzang NJ, Thompson IM, Hussain MH

Urology.. 2011 May 77 (5):1172-6. Epub 02/21/2011.

Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer.

Huang CH, Williamson SK, Van Veldhuizen PJ, Hsueh CT, Allen A, Tawfik O, Wick J, Smith H, Uypeckcuat AM, Mayo M, Kelly K

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.. 2011 February 6 (2):372-7. Epub 1900 01 01.

Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis.

Haque I, Mehta S, Majumder M, Dhar K, De A, McGregor D, Van Veldhuizen PJ, Banerjee SK, Banerjee S

Molecular cancer.. 2011 January 1310 :8. Epub 01/13/2011.

Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.

Wu J, Henderson C, Feun L, Van Veldhuizen P, Gold P, Zheng H, Ryan T, Blaszkowsky LS, Chen H, Costa M, Rosenzweig B, Nierodzik M, Hochster H, Muggia F, Abbadessa G, Lewis J, Zhu AX

Investigational new drugs.. 2010 October 28 (5):670-6. Epub 06/30/2009.

Tumor cell-derived PDGF-B potentiates mouse mesenchymal stem cells-pericytes transition and recruitment through an interaction with NRP-1.

Dhar K, Dhar G, Majumder M, Haque I, Mehta S, Van Veldhuizen PJ, Banerjee SK, Banerjee S

Molecular cancer.. 2010 August 59 :209. Epub 08/05/2010.

Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer.

Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN, Van Veldhuizen PJ, Quinn DI, Vogelzang NJ, Thompson IM, Hussain MH

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2010 June 116 (11):3028-34. Epub 05/18/2010.

Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma.

Hashmi MH, Van Veldhuizen PJ

Expert opinion on biological therapy.. 2010 May 10 (5):807-17. Epub 1900 01 01.

S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach.

Blanke CD, Chansky K, Christman KL, Hundahl SA, Issell BF, Van Veldhuizen PJ, Budd GT, Abbruzzese JL, Macdonald JS

American journal of clinical oncology.. 2010 April 33 (2):117-20. Epub 1900 01 01.

Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium.

Petrylak DP, Tangen CM, Van Veldhuizen PJ, Goodwin JW, Twardowski PW, Atkins JN, Kakhil SR, Lange MK, Mansukhani M, Crawford ED

BJU international.. 2010 February 105 (3):317-21. Epub 11/02/2009.

Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.

Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, Van Veldhuizen PJ, Friedman N, Reda D, Warren S, Garewal H

The Journal of urology.. 2009 November 182 (5):2257-64. Epub 09/16/2009.

A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.

Van Veldhuizen PJ, Hussey M, Lara PN, Mack PC, Gandour-Edwards R, Clark JI, Lange MK, Crawford DE

American journal of clinical oncology.. 2009 October 32 (5):453-9. Epub 1900 01 01.

Crocetin inhibits pancreatic cancer cell proliferation and tumor progression in a xenograft mouse model.

Dhar A, Mehta S, Dhar G, Dhar K, Banerjee S, Van Veldhuizen P, Campbell DR, Banerjee SK

Molecular cancer therapeutics.. 2009 February 8 (2):315-23. Epub 02/10/2009.

Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes.

Beer TM, Goldman B, Synold TW, Ryan CW, Vasist LS, Van Veldhuizen PJ, Dakhil SR, Lara PN, Drelichman A, Hussain MH, Crawford ED

Clinical genitourinary cancer.. 2008 September 6 (2):103-9. Epub 1900 01 01.

VEGF-A165 induces human aortic smooth muscle cell migration by activating neuropilin-1-VEGFR1-PI3K axis.

Banerjee S, Mehta S, Haque I, Sengupta K, Dhar K, Kambhampati S, Van Veldhuizen PJ, Banerjee SK

Biochemistry.. 2008 March 1847 (11):3345-51. Epub 02/20/2008.

2-Methoxyestradiol modulates beta-catenin in prostate cancer cells: a possible mediator of 2-methoxyestradiol-induced inhibition of cell growth.

Van Veldhuizen PJ, Ray G, Banerjee S, Dhar G, Kambhampati S, Dhar A, Banerjee SK

International journal of cancer.. 2008 February 1122 (3):567-71. Epub 1900 01 01.

The validity of the dissociative disorders.

Van Veldhuizen PJ

Psychotherapy and psychosomatics.. 2007 76 (1):58-9; author reply 59-60. Epub 1900 01 01.

Effects of soy phytoestrogens on the prostate.

Goetzl MA, Van Veldhuizen PJ, Thrasher JB

Prostate cancer and prostatic diseases.. 2007 10 (3):216-23. Epub 02/20/2007.

Dose effect of soy supplementation in prostate cancer: a pilot study.

van Veldhuizen PJ, Thrasher JB, Ray G, Cherian R, Ward J, Holzbeierlein J, Gutow S, Banerjee SK

Oncology reports.. 2006 December 16 (6):1221-4. Epub 1900 01 01.

Dysgenetic hypoplastic kidney simulating metastatic lung carcinoma.

Huang CH, McGregor DH, Haltaufderhyde V, Victor F, VanVeldhuizen P

Lung cancer : journal of the International Association for the Study of Lung Cancer.. 2006 October 54 (1):125-9. Epub 08/22/2006.

Modulation of cell-cycle regulatory signaling network by 2-methoxyestradiol in prostate cancer cells is mediated through multiple signal transduction pathways.

Ray G, Dhar G, Van Veldhuizen PJ, Banerjee S, Saxena NK, Sengupta K, Banerjee SK

Biochemistry.. 2006 March 2145 (11):3703-13. Epub 1900 01 01.

A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.

Van Veldhuizen PJ, Faulkner JR, Lara PN, Gumerlock PH, Goodwin JW, Dakhil SR, Gross HM, Flanigan RC, Crawford ED,

Cancer chemotherapy and pharmacology.. 2005 July 56 (1):39-45. Epub 03/25/2005.

Growth factors involved in prostate carcinogenesis.

Kambhampati S, Ray G, Sengupta K, Reddy VP, Banerjee SK, Van Veldhuizen PJ

Frontiers in bioscience : a journal and virtual library.. 2005 May 110 :1355-67. Epub 05/01/2005.

Stimulation of MCF-7 tumor progression in athymic nude mice by 17beta-estradiol induces WISP-2/CCN5 expression in xenografts: a novel signaling molecule in hormonal carcinogenesis.

Ray G, Banerjee S, Saxena NK, Campbell DR, Van Veldhuizen P, Banerjee SK

Oncology reports.. 2005 March 13 (3):445-8. Epub 1900 01 01.

Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study.

Urba SG, Chansky K, VanVeldhuizen PJ, Pluenneke RE, Benedetti JK, Macdonald JS, Abbruzzese JL,

Investigational new drugs.. 2004 January 22 (1):91-7. Epub 1900 01 01.

Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study.

Van Veldhuizen PJ, Reed G, Aggarwal A, Baranda J, Zulfiqar M, Williamson S

Cancer.. 2003 November 198 (9):1855-62. Epub 1900 01 01.

Psychiatrists' attitudes toward dissociative disorders diagnoses.

van Veldhuizen PJ

The American journal of psychiatry.. 2000 July 157 (7):1180-2. Epub 1900 01 01.

Treatment of vitamin D deficiency in patients with metastatic prostate cancer may improve bone pain and muscle strength.

Van Veldhuizen PJ, Taylor SA, Williamson S, Drees BM

The Journal of urology.. 2000 January 163 (1):187-90. Epub 1900 01 01.

Urokinase-type plasminogen activator expression in human prostate carcinomas.

Van Veldhuizen PJ, Sadasivan R, Cherian R, Wyatt A

The American journal of the medical sciences.. 1996 July 312 (1):8-11. Epub 1900 01 01.

Chylothorax: a complication of a left subclavian vein thrombosis.

Van Veldhuizen PJ, Taylor S

American journal of clinical oncology.. 1996 April 19 (2):99-101. Epub 1900 01 01.

Metoclopramide-induced sulfhemoglobinemia.

Van Veldhuizen PJ, Wyatt A

The American journal of gastroenterology.. 1995 June 90 (6):1010-1. Epub 1900 01 01.

Case report: cholangiocarcinoma and hypercalcemia.

Davis JM, Sadasivan R, Dwyer T, Van Veldhuizen P

The American journal of the medical sciences.. 1994 May 307 (5):350-2. Epub 1900 01 01.

Decreased fibrinolytic potential in patients with idiopathic avascular necrosis and transient osteoporosis of the hip.

Van Veldhuizen PJ, Neff J, Murphey MD, Bodensteiner D, Skikne BS

American journal of hematology.. 1993 December 44 (4):243-8. Epub 1900 01 01.

Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer.

Sadasivan R, Morgan R, Jennings S, Austenfeld M, Van Veldhuizen P, Stephens R, Noble M

The Journal of urology.. 1993 July 150 (1):126-31. Epub 1900 01 01.

Evaluation of neoplastic spinal cord compressions.

Van Veldhuizen PJ, Stephens RL

Kansas medicine : the journal of the Kansas Medical Society. 1993 May 94 (5):130-2. Epub 1900 01 01.

p53 expression in incidental prostatic cancer.

Van Veldhuizen PJ, Sadasivan R, Cherian R, Dwyer T, Stephens RL

The American journal of the medical sciences.. 1993 May 305 (5):275-9. Epub 1900 01 01.

Mutant p53 expression in prostate carcinoma.

Van Veldhuizen PJ, Sadasivan R, Garcia F, Austenfeld MS, Stephens RL

The Prostate.. 1993 22 (1):23-30. Epub 1900 01 01.

Takayasu arteritis presenting as retinal and vertebrobasilar ischemia.

Edwards KK, Lindsley HB, Lai CW, Van Veldhuizen PJ

The Journal of rheumatology.. 1989 July 16 (7):1000-2. Epub 1900 01 01.